Company / SG&A per Share
ENANTA PHARMACEUTICALS INC SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$2.50
FY2025
5-year range
$1.31 / $2.50
FY2021-FY2025
Trend
+15.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A per Share has increased for 9 consecutive years, from $0.54 in FY2016 to $2.50 in FY2025.
Based on SEC 10-K filings.
2.50 in FY2025 with a 5-year CAGR of +16.0%.
Increased from $1.56 to $2.50 over the past 2 years.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +22.7%
- 5-Year CAGR
- +16.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's sg&a per share has grown for 9 consecutive years.
- In FY2025, sg&a per share increased 15.5% year-over-year.
- Lowest sg&a per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.50 | +15.5% |
| FY2024 | $2.16 | +38.0% |
| FY2023 | $1.56 | +15.8% |
| FY2022 | $1.35 | +3.4% |
| FY2021 | $1.31 | +9.9% |
| FY2020 | $1.19 | +11.2% |
| FY2019 | $1.07 | +20.6% |
| FY2018 | $0.89 | +24.7% |
| FY2017 | $0.71 | +32.9% |
| FY2016 | $0.54 | +60.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026